Clinical trial NCT04951440: Study on the Effectiveness and Safety of Nitrone for Injection in Patients With Acute Ischemic Stroke
Official title: Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Trial to Evaluate the Effectiveness and Safety of Nitrone for Injection in Patients With Acute Ischemic Stroke
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Ischemic Stroke
Keywords: Nitroxazine
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
Collaborators: name: Capital Medical University
First posted: 2021-07-06
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of the study: To evaluate the effect of nitrosone 1 special for patients with acute ischemic cerebral stroke. The secondary purpose of the study: To evaluate the effectiveness of the injection of nitrosone I. T for loyal patients with acute ischemic stroke All women think.

Detailed description: The main purpose of the study: To evaluate the effect of nitrosone 1 special for patients with acute ischemic cerebral stroke. The secondary purpose of the study: To evaluate the effectiveness of the injection of nitrosone I. T for loyal patients with acute ischemic stroke All women think.

This experiment adopts randomized, double-blind, placebo-controlled parallel design. In patients with acute, ischemic cerebral rate as the research object, after selected exclusion standard screening, if doesn't fit or don't agree with thrombolysis subjects, giving from connect to test a drug or a placebo treatment, if appropriate and agreed to thrombolysis of the subjects with an experimental drug or placebo after thrombolysis treatment.Intervention group: 30) min uniform given 1400 mg intravenous drip injection with ketone wordy, nitrate dosing volume 100 ml. Day delivery, two intervals of 12 h, for seven days in a row, namely to 14 times in total.The placebo group: 30 min to 100 ml placebo at a constant speed intravenous drip (sodium chloride injection), dosing W times a day, 12 h, for seven days in a row, namely to 14 times in total.During treatment, participants in the group after injection with nitrate ketone oxazine (giving injections with nitrate ketone oxazine time window \< 6 h, that is, from "the last look normal time" to start infusion nitrate obviously time) or placebo and other foundation treatment. Record for the first time to give the time of nitrate ketone oxazine or placebo for injection, lie between 8 and 12 h 2 times to medicine."After 12 h dosing interval, until finish to 14 times (for convenient subjects out of the hospital and acceptable to 13).Allow this study drug and placebo and thrombolysis drug dosing dual channel at the same timeStop to test drug or placebo, in the group of 8 days, 14 days, 30 days, the 90th day to evaluate curative effect, respectively.In the I the ili is not ah into subgroups according to try tii statistical treatment.

Eligibility criteria: Inclusion Criteria:

* (1) the age 18 to 65 years of age, gender not limited (including 18 and 65 years old) :(2) according to the Chinese guide of diagnosis and treatment of acute ischemic stroke (2018) with a diagnosis of acute ischemic strokeThe lender;(3) from the "look" normal time to start infusion for lamictal nitrate or placebo \< 6 hours, to wake up or stroke due to accurately obtain aphasia, disturbance of consciousness and other symptom onset time, shall be made in patients with the last performance of normal time I;(4) after the first or the last disease incidence after the more good (mkS score 0-1) disease patients again;(5) at the four points \< NIHISS score \< 24 points;(6) from beginning to the last delivery signed informed consent is willing to take effective contraceptive measures within 6 months after:Understand and abide by the research process and voluntary participation, and sign the informed consent form (informed consent signed by the person or legal representative voluntary).

Exclusion Criteria:

* (1) the patients with recurrent cerebral infarction incidence before mRS score \> 1;(2) unconsciousness (NIHSS score la 22 points);(3) neural imaging examination (CT/MRI) suggests intracerebral hemorrhagic disease (such as: hemorrhagic cerebral apoplexy, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.)(4) imaging examination showed middle cerebral artery infarction area \> one-third, or ASPECT score \< 7 points:(5) transient ischemic attack (TIA) :(6) to prepare or have lines endovascular treatment of patients;(7), severe renal insufficiency: creatinine clearance \< 30 mL/min (Cockcroft - Gault formula), blood urea nitrogen and/or muscle \> 1.5 times the upper limit of normal value, or other serious kidney function is not complete disease known;Severe liver function damage (8) : ALT, AST \> 1.5 times the upper limit of normal value, or other known liver diseases such as acute or chronic hepatitis, liver cirrhosis, etc;(9) hospital routine blood tip: white blood cells \< normal lower limit; Hemoglobin \< normal lower limit; Hospital to check blood sugar \< 2.8 tendency for L, or \> 16.8 mmo / /; Temperature \> 38 c; Other laboratory examination with clinical significance is unusual, and the researchers of decision should not be set;(10) are poorly controlled hypertension, systolic blood pressure \> 220 MMHG 2 120 MMHG and/or diastolic blood pressure:(11) heart rate \< 40 times/min and/or heart rate \> 120 times/min: nearly six months or line of interventional therapy of acute myocardial infarction (ami), patients with heart failure (in the patients with NYHA class for 111-1 v);(12) in patients with epilepsy: merging other patients with mental illness to cooperation or unwilling to cooperation; Patients with dementia.(13) of malignant tumor, blood, digestive serious illness, or other system.(14) on experimental drug or similar components or materials used for imaging examination allergies;(15) blood positie pregnancy, pregnancy and lactation women:

Primary outcomes:
measure: Percentage of patients with NIHSS ≤1 or a reduction of 4 or more points from baseline
timeFrame: On the 14th day of treatment
Secondary outcomes:
measure: The change of MRS score
timeFrame: 30th day and the 90th day of treatment
Other outcomes:
Locations:
city: Beijing
country: China
facility: : Beijing Dan's self technology co., LTD.
city: Beijing
country: China
facility: Tiantan Hospital, Capital Medical University
Study officials:
affiliation: Capital Medical University
name: Yongjun Wang
role: STUDY_CHAIR
References: